Tara Henson
Family Medicine · Greensburg, KYNPI 1366515363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 210 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$610
- AstraZeneca$531
- Lilly USA, LLC$505
- Pfizer$219
- Boehringer Ingelheim$170
- Novo Nordisk$163
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,58697%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $610 |
| AstraZeneca | 18 | $531 |
| Lilly USA, LLC | 37 | $505 |
| Pfizer | 14 | $219 |
| Boehringer Ingelheim | 11 | $170 |
| Novo Nordisk | 11 | $163 |
| Astellas Pharma US Inc | 4 | $147 |
| Shield Therapeutics Inc | 2 | $142 |
| Novartis | 8 | $130 |
| GSK | 7 | $105 |
| Merck | 5 | $85 |
| Abbott | 5 | $82 |
| Amgen | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 4 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Medtronic | 1 | $56 |
| Nestle Healthcare Nutrition Inc. | 3 | $52 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| Melinta Therapeutics, LLC | 2 | $41 |
| Johnson & Johnson | 3 | $36 |
| Lundbeck LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Cipher Pharmaceuticals US LLC | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,681 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 165 | $166,557 |
| JardianceEmpagliflozin | 163 | $148,363 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $71,100 |
| OtezlaApremilast | 11 | $53,359 |
| EliquisApixaban | 57 | $41,751 |
| VraylarCariprazine Hcl | 28 | $39,860 |
| JanuviaSitagliptin Phosphate | 41 | $38,395 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $34,584 |
| MounjaroTirzepatide | 27 | $34,241 |
| Nurtec OdtRimegepant Sulfate | 33 | $33,250 |
| TradjentaLinagliptin | 40 | $33,080 |
| RybelsusSemaglutide | 19 | $31,142 |
| RexultiBrexpiprazole | 20 | $28,712 |
| MyrbetriqMirabegron | 35 | $25,374 |
| FarxigaDapagliflozin Propanediol | 31 | $25,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $163 | $197,699184 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $170 | $193,459218 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $105 | $75,573106 claims |
| PfizerEliquis, Nurtec Odt | $219 | $75,00190 claims |
| AmgenOtezla | $77 | $53,35911 claims |
| Lilly USA, LLCMounjaro, Trulicity | $505 | $51,07439 claims |
| AbbVieVraylar, Linzess | $610 | $50,61646 claims |
| MerckJanuvia | $85 | $38,39541 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $531 | $31,62142 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $29 | $28,71220 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $25,37435 claims |
| Johnson & JohnsonXarelto | $36 | $14,35711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Greensburg
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
- Derek JonesAshland$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.